Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.

被引：1
|
作者：
de Rosa, F.
Agostini, V.
Di Girolamo, S.
Andreone, P.
Trevisani, F.
Bolondi, L.
Pinna, A. D.
Serra, C.
Golfieri, R.
Biasco, G.
Brandi, G.
机构：
[1] Univ Bologna, Bologna, Italy
[2] Azienda Osped Bologna, Policlin S Orsola Malpighi, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14608
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, Mian
    He, Chaosheng
    Huang, Jinkun
    Lin, Qizhan
    Zou, Lixin
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [32] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, M.
    He, C.
    Huang, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 71 - 71
  • [33] Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
    Kaseb, Ahmed O.
    Morris, Jeffrey S.
    Iwasaki, Michiko
    Al-Shamsi, Humaid O.
    Raghav, Kanwal Pratap Singh
    Girard, Lauren
    Cheung, Sheree
    Van Nguyen
    Elsayes, Khaled M.
    Xiao, Lianchun
    Abdel-Wahab, Reham
    Shalaby, Ahmed S.
    Hassan, Manal
    Hassabo, Hesham M.
    Wolff, Robert A.
    Yao, James C.
    ONCOTARGETS AND THERAPY, 2016, 9 : 773 - 780
  • [34] Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer
    Roviello, Giandomenico
    Aprile, Giuseppe
    Catalano, Martina
    Ramello, Monica
    Conca, Raffaele
    Petrioli, Roberto
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2022, 23 (15) : 1788 - 1791
  • [35] Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer
    Shi, Sheng-bin
    Wang, Meng
    Niu, Zuo-xing
    Tang, Xiao-yong
    Liu, Quan-yun
    PANCREATOLOGY, 2012, 12 (06) : 475 - 479
  • [36] Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
    Qin, He-nan
    Ning, Zhen
    Sun, Rui
    Jin, Chen-xing
    Guo, Xin
    Wang, A-man
    Liu, Ji-wei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Irinotecan/mitomycin C (IRI/MMC) combination as second-line chemotherapy in patients with metastaic gastric carcinoma: A phase II study.
    Narimanov, M.
    Kanagavel, D.
    Tryakin, A.
    Tjulandin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
    N. Baize
    A. Abakar-Mahamat
    N. Mounier
    F. Berthier
    F. X. Caroli-Bosc
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 549 - 555
  • [39] Capecitabine and oxaliplatin as second-line chemotherapy in patients with advanced colorectal carcinoma
    Gennatas, C
    Mallas, E
    Samanidis, L
    Polydorou, A
    Karamanolis, G
    Voros, D
    Komporozos, V
    PROCEEDINGS OF THE 9TH BIENNIAL CONGRESS OF THE EUROPEAN COUNCIL OF COLOPROCTOLOGY, ECCP, 2003, : 217 - 221
  • [40] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Xuyuan Li
    Wen Lin
    Hongbiao Wang
    Wenzhao Lin
    Suiling Lin
    Yingcheng Lin
    Medical Oncology, 2013, 30
12345